NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 207 filers reported holding NEKTAR THERAPEUTICS in Q1 2017. The put-call ratio across all filers is 0.37 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2016 | $141,000 | -28.8% | 11,500 | 0.0% | 0.01% | -31.6% |
Q3 2016 | $198,000 | -13.2% | 11,500 | -28.1% | 0.02% | -17.4% |
Q2 2016 | $228,000 | +3.6% | 16,000 | 0.0% | 0.02% | 0.0% |
Q1 2016 | $220,000 | -18.5% | 16,000 | 0.0% | 0.02% | -17.9% |
Q4 2015 | $270,000 | +45.2% | 16,000 | -5.8% | 0.03% | +40.0% |
Q3 2015 | $186,000 | -12.3% | 16,985 | 0.0% | 0.02% | -4.8% |
Q2 2015 | $212,000 | +13.4% | 16,985 | 0.0% | 0.02% | +10.5% |
Q1 2015 | $187,000 | -28.9% | 16,985 | 0.0% | 0.02% | -34.5% |
Q4 2014 | $263,000 | +25.8% | 16,985 | -1.8% | 0.03% | +16.0% |
Q3 2014 | $209,000 | -11.8% | 17,300 | -6.5% | 0.02% | -16.7% |
Q2 2014 | $237,000 | +12.9% | 18,500 | +6.9% | 0.03% | +7.1% |
Q1 2014 | $210,000 | +7.1% | 17,300 | 0.0% | 0.03% | +12.0% |
Q4 2013 | $196,000 | +4.3% | 17,300 | -3.9% | 0.02% | +4.2% |
Q3 2013 | $188,000 | -19.7% | 18,000 | -11.3% | 0.02% | -25.0% |
Q2 2013 | $234,000 | – | 20,300 | – | 0.03% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Camber Capital Management LP | 2,000,000 | $67,200,000 | 3.35% |
First Light Asset Management, LLC | 763,403 | $25,650,000 | 3.33% |
BRIDGER MANAGEMENT, LLC | 1,238,489 | $41,613,000 | 3.29% |
Rhenman & Partners Asset Management AB | 734,445 | $24,677,000 | 2.89% |
BB BIOTECH AG | 2,020,676 | $67,895,000 | 1.71% |
Gs Investments, Inc. | 54,200 | $1,821,120,000 | 1.43% |
Artal Group S.A. | 900,000 | $30,240,000 | 1.24% |
Cormorant Asset Management, LP | 500,000 | $16,800,000 | 1.14% |
TOBAM | 640,547 | $21,522,000 | 1.09% |
Bellevue Group AG | 430,026 | $14,449,000 | 0.80% |